To compare the effects of topical collagen and hydrocolloid on pressure ulcer healing. 
ressure ulcers are a serious problem for the older population because of associated pain, osteomyelitis, sepsis, and mortality. 1, 2 The prevalence of pressure ulcers reaches 24% of residents in nursing homes. 1, 3, 4 The annual cost of pressure ulcer care in the United States exceeds $1.3 billion. 5, 6 Although many pressure ulcers originate in acute care settings, ongoing ulcer care occurs outside the hospital and in long-term care facilities. 1, 7, 8 The standard treatment for a clean, full-thickness or partial-thickness pressure ulcer is a moist topical dressing. 1, 9 Hydrocolloid is a moist, vapor-permeable, occlusive wound dressing. While maintaining a moist environment for wound healing, 10 hydrocolloid also increases adenosine triphosphate and energy generation 11 and enhances wound granulation and re-epithelialization. 12, 13 Although hydrocolloid helps Stage II and Stage III pressure ulcers heal faster than saline-soaked gauze. 6, 13 Some studies suggest that hydrocolloid occlusive dressings may dissolve or degrade and impair wound healing by being incorporated into the wound. 14, 15 Other studies suggest that deep ulcers do not respond to hydrocolloid as well as superficial ulcers do. 10, 16 Consequently, some roles for hydrocolloid remain controversial in pressure ulcer management.
An alternative treatment for pressure ulcers may be collagen. Various collagen products are classified as wound dressings and approved by the U.S. Food and Drug Administration. 17 Collagen formulations include sheets, pads, particles, and gels. 17 Wound dressing collagen is extracted from bovine skin and is predominantly type I collagen with small proportions of type III and type V fibers. 18, 19 The mechanism for collagen's action in wound healing is uncertain. Proposed mechanisms for collagen are related to platelet binding, macrophage and neutrophil accumulation, fibroblast deposition, angiogenesis, epithelialization, and granulation. 19, 20 Uncontrolled or small trials suggest favorable results with topical collagen in the treatment of pressure ulcers, burns, venous ulcers, and surgical wounds. [18] [19] [20] [21] When compared with various topical control therapies, collagen appears to enhance granulation, decrease pain, and facilitate healing. [18] [19] [20] [21] Collagen granules may be applied to the wound base in deep ulcers with undermined edges. Theoretically, deep pressure ulcers might heal better with collagen than with occlusive dressing applied to the skin surface.
The authors are unaware of previous randomized, controlled, blinded trials to compare collagen with hydrocolloid. The objective of this study was to compare the effects of topical collagen with those of topical hydrocolloid on the healing of Stage II or III pressure ulcers.
METHODS
The design of the study was a randomized, parallel-group, single-blind (outcome assessor), controlled trial. The Peoria Community Institutional Review Board and the Illinois Department of Public Health approved and monitored the study. This research complied with the ethical rules for human experimentation stated in the Declaration of Helsinki.
Study participants were residents of 11 skilled nursing facilities in central Illinois. Included patients were older than 18 with at least one pressure ulcer, Stage II or III, as defined by the National Pressure Ulcer Advisory Panel. 9 Exclusion criteria were hypersensitivity to collagen or bovine products, concomitant investigational therapy, previous enrollment in the trial, osteomyelitis, cellulitis, malnutrition, ulcers covered by eschar or necrotic material, ulcers covered by orthopedic casts or devices, burn ulcers, diabetic foot ulcers distal to tarsals, life expectancy less than 8 weeks, and anticipated transfer to acute care within 8 weeks. For study purposes, osteomyelitis, cellulitis, and malnutrition were defined as active diagnoses noted by primary physicians. Nursing home nurses screened potentially eligible patients. Patients excluded only because of eschar or necrotic material were rescreened for potential eligibility any time after successful debridement. After consultation with attending physicians, investigators completed the informed consent process with patients and healthcare surrogates. All patients received standard nursing home interventions to optimize nutrition, activity, and mobility and minimize moisture, friction, and shear.
Study treatment involved only one ulcer per patient. Treatment assignment was in a 1:1 ratio to daily Type I collagen (Medifil, Kollagen, BioCore, Topeka, KS) or twice-weekly hydrocolloid (DuoDerm, ConvaTec, E.R. Squibb & Sons, Inc., Princeton, NJ). Investigators trained nurses at each site to assure standardized protocol adherence. Before each study treatment, nurses irrigated the ulcer with sterile saline then sprinkled sterile collagen particles (open label) in a thin continuous layer over the ulcer bed. Next, nurses covered the collagen ulcer with dry gauze to allow spontaneous drainage. If hydrocolloid was the assignment, then nurses applied hydrocolloid (open label) and rimmed the perimeter with tape. Nurses replaced hydrocolloid approximately every fourth day, or sooner if soiled. Ancillary (nonprotocol) wound treatments of the study ulcer were prohibited during the trial.
Study treatment duration was 8 weeks because randomized, controlled trials of hydrocolloid show complete healing rates of 22% to 89% within 8 weeks. 6, 13 Patients terminated treatment before 8 weeks if the study ulcer healed completely or if treatment failed. The definition of complete healing was epithelial tissue covering 100% of the study ulcer. 22 The following conditions defined failure during treatment: cellulitis, new devitalized tissue requiring debridement, or increased ulcer area during 4 consecutive weeks.
The sample size calculation employed the procedure for categorical variables 23 with 80% power and two-sided alpha of 0.05. The null hypothesis was no difference between treatment groups to achieve complete ulcer healing within 8 weeks. For collagen recipients, the estimated healing rate was 80%, a value obtained from a pilot trial of eight subjects. For hydrocolloid patients, the estimated healing rate was 56%, an average value obtained from randomized, controlled trials of Stage II and Stage III ulcers. 6, 13 The sample size estimate assumed that 24% difference in healing rates was clinically important. The estimated sample size was 58 patients per group, and estimated dropout rate was 10%. After adjusting sample size for dropouts, the total sample size was 128 patients. One interim analysis was planned after 60 patients enrolled. The interim analysis employed the method of stochastic curtailment. 24 The randomization scheme was a stratified, blocked design. Diabetes mellitus was the stratification variable because of uncertainty about the prognostic role of diabetes mellitus in healing rate. [25] [26] [27] The block size was a random number between 4 and 10. Personnel unassociated with the trial created the assignment list with a computerized random number generator 28 and locked the list in a site unknown to study and nursing home personnel. After documenting informed consent and eligibility, the study nurse obtained treatment assignment from the central randomization facility via telephone.
The primary efficacy endpoint was the proportion of pressure ulcers completely healed within 8 weeks of randomization. Secondary efficacy endpoints were time to ulcer healing, area healed per day, [29] [30] [31] and linear healing of the wound edge. 31, 32 Outcome assessment occurred at baseline, then once weekly by investigators blinded to treatment assignment. Nurses removed test or control treatment and irrigated the study ulcer with sterile saline immediately before blinded outcome assessors arrived at bedside. Ulcer irrigation before observation served to maintain the blind but precluded accurate assessment of exudate and slough. Efficacy assessment involved ulcer photography with validated, standardized techniques. [33] [34] [35] Quantitative analysis of calibrated photographs employed a computer-aided system with image capture and morphometric software (MCID, Imaging Research Inc., St. Catharines, Ontario, Canada). An investigator (JCM) blinded to treatment assignment performed all image analyses of ulcer area and perimeter. During each study visit, the blinded observers used validated, standardized techniques to record ulcer length, width, and appearance. 22 Blinded outcome assessors measured center ulcer depth (in mm) with a sterile probe. 36 The effectiveness of the blind was assessed using questionnaires administered to the observers. Cost analysis employed techniques similar to previous pressure ulcer studies. 6, 10, 13, 37 STATISTICAL ANALYSIS Primary, prespecified analyses were performed according to the principle of intention to treat. For categorical variables, comparisons involved chi-square or Fisher exact tests. Comparisons for continuous variables employed t tests or Mann-Whitney tests when appropriate. Two-sided P values less than .05 were considered significant. Adjustment for multiple comparisons involved the Bonferroni inequality. Analysis of time to complete healing used survival methods. Pairwise comparisons between groups employed the log-rank test with event rates calculated by the Kaplan-Meier method.
Exploratory logistic regression analyses evaluated the relationship between the primary endpoint and covariates identified by literature review. Covariates included the following variables associated with pressure ulcer development: age, 38 weight, 25 blood pressure, 7 Braden score, 7 dementia, 26 diabetes mellitus, 25 nursing home, 26 and sex. 38 Covariates associated with ulcer healing were area, 39 depth, 40 age, 41 and stage. 41 Covariates chosen from recommendations of expert consensus were serum albumin 1 and ulcer duration before enrollment. 30 Variables significant at the .10 level were examined further in a multivariate model with forward and backward stepwise procedures (SPSS for Windows, Release 9.0.0, SPSS Inc., Chicago, IL).
RESULTS
The investigators enrolled 65 patients between May 4, 2000, and June 12, 2001 . The median follow-up of 65 patients was 35 days. The last study follow-up was August 9, 2001 . The flow of patients through the trial appears in Figure 1 . The study population had a median age of 83.1; 63% (41/65) were female, 46% (30/65) had dementia, and 32% (21/65) had diabetes mellitus. The median ulcer duration was 4 weeks, with 80% (52/65) Stage II ulcers and 20% (13/65) Stage III ulcers. The most common body sites for study ulcers were sacral-coccyx 52% (34/65), heel 18% (12/65), and ankle 12% (8/65). Treatment groups were similar in their demographic and clinical characteristics (Table 1) . Although ulcer duration and area appeared different at baseline, their large variances produced no statistically significant differences. At the end of study treatment, the collagen and hydrocolloid groups remained comparable with respect to serum albumin and Braden scores ( Table 1 ). The drop-out rate unrelated to study treatment ( Figure 1 ) was 17% (6/35) in the collagen group and 17% (5/30) in the hydrocolloid group ( P ϭ .779).
The same group of blinded investigators (LWS, JFG, RGM, SAA) performed bedside ulcer measurement, assessed healing, and guessed treatment assignment at each visit. After adjustment for repeated measures, there were no significant associations between blinded investigators' guesses and true treatment assignment (smallest P ϭ .376).
One blinded investigator (JCM) guessed treatment assignment and measured all ulcer photographs via image analysis. The image analyst's guesses were not associated with true assignment ( P ϭ .924).
One interim analysis occurred after 65 of 128 patients enrolled in the study. The stochastic curtailment procedure 24 tested the following assumptions for the primary endpoint in 63 hypothetical future patients: the null hypothesis, the alternative hypothesis (estimate collagen would heal 80%, estimate hydrocolloid would heal 56%), and the current healing rates ( Table 2 ). The probabilities of rejecting the null hypothesis after enrolling 63 more subjects under the respective assumptions were 3%, 25%, and 3.6%. The probabilities did not favor continuation, so the trial was curtailed. Table 2 shows the results of the primary and secondary endpoints. Complete healing rates were the same at 8 weeks. At earlier time points, between-group healing rates (raw) were comparable: collagen healed 17% (6/35) within 2 weeks and 40% (14/35) within 4 weeks, hydrocolloid healed 20% (6/30) within 2 weeks and 30% (9/30) within 4 weeks. In the Kaplan-Meier analysis, there was no significant difference (log rank 0.68, P ϭ .409) in time to complete healing between collagen and hydrocolloid treatments (Figure 2 ). For collagen patients, the mean healing time was 5 weeks (95% confidence interval (CI) ϭ 4-6). The hydrocolloid recipients had mean healing time of 6 weeks (95% CI ϭ 5-7). The results in Table 2 consistently showed no significant differences between collagen and hydrocolloid for any primary and secondary efficacy endpoints.
In exploratory univariate analyses, baseline measures of ulcer stage, depth, duration, and area were the only covariates associated with complete healing within 8 weeks ( P Ͻ .10). Inspection of the data revealed significant skew in depth, duration, and area. Consequently, these continuous variables were analyzed as raw, rank-transformed, and categorical data. Examination of correlation matrices for the covariates revealed no significant multicollinearity. Analysis of interaction variables revealed no significant interactions. The multivariate logistic regression model entered stage, depth, duration, and area. In the model, only ulcer depth (odds ratio (OR) ϭ 0.56, 95% CI ϭ 0.38-0.81, P ϭ .002) remained a significant predictor of complete healing within 8 weeks.
During exploratory analyses, a bias in treatment outcomes secondary to imbalanced baseline covariates was hypothesized. Stratified Kaplan-Meier analyses addressed the hypothesis for the following covariates: depth, stage, duration, area, and diabetes mellitus. Continuous variables were re-examined as dichotomous variables using arbitrary breakpoints defined in Table 3 .
In post hoc analysis, baseline ulcer depth was dichotomized at the mean value and analyzed (Table 3, Figure 3) . The raw healing rates (within 8 weeks) for ulcers 2 to 21 mm deep were 33% (5/15) for collagen recipients and 9% (1/11) for hydrocolloid recipients ( P ϭ .197). Ulcers with a depth of 0 to 1 mm had mean healing time of 4 weeks (95% CI ϭ 3.5-5.0). For ulcers deeper than 2 mm, the mean healing time was 7 weeks (95% CI ϭ 6-8). After adjustment for baseline ulcer depth, there was no significant difference in healing time between collagen and hydrocolloid (log rank 1.45, P ϭ .229).
Exploratory analyses related ulcer stage to healing outcome (Table 3) . Forty-four percent of Stage II ulcers (23/52) healed within 4 weeks, and the mean healing time was 5 weeks (95% CI ϭ 4-6). No Stage III ulcers healed within 4 weeks, and the mean healing time was 7.6 weeks (95% CI ϭ 7-8). After adjustment for ulcer stage, there was no significant difference in healing time between collagen and hydrocolloid (log rank 0.5, P ϭ .477). Note: At the end of study, treatment groups remained comparable; serum albumin was 3.1 Ϯ 0.4 g/dL (mean Ϯ standard deviation (SD)) for collagen patients and 3.2 Ϯ 0.5 g/dL for hydrocolloid patients. End-of-study Braden scores were 13 Ϯ 3 for collagen recipients and 13 Ϯ 4 for hydrocolloid patients. * Ulcer duration before baseline assessment was obtained from nursing home nurse documentation. † Area calculation used ellipse equation ϭ 1 ⁄ 4 ϫ (pi) ϫ (long axis length) ϫ (short axis length). Ulcer duration (before baseline) was the subject of post hoc analysis (Table 3) . If ulcer duration was 8 weeks or less, then mean healing time was 5 weeks (95% CI ϭ 4-6). For ulcers extant 9 or more weeks, the mean healing time was 5 weeks (95% CI ϭ 4-7). Six of 16 patients with ulcer duration longer than 9 weeks had duration longer than 24 weeks, and none (0/6) healed within 8 weeks. After adjustment for ulcer duration, there was no significant difference in healing time between collagen and hydrocolloid (log rank 0.5, P ϭ .820).
Exploratory analysis addressed baseline ulcer area as a categorical variable (Table 3) . For ulcers with baseline area less than 126 mm 2 , the mean healing time was 5 weeks (95% CI 4-6). Ulcers with area greater than 126 mm 2 had mean healing time of 6 weeks (95% CI ϭ 5-7). After adjustment for baseline ulcer area, there was no significant difference in healing time between collagen and hydrocolloid (log rank 0.44, P ϭ .508).
Diabetes mellitus was the stratification variable during randomization. During post hoc analysis, diabetes mellitus was not found to be associated with healing outcome (P ϭ .858). Diabetes mellitus was not correlated significantly with other baseline covariates, including ulcer stage, depth, area, or duration. After adjustment for diabetes mellitus, there was no significant difference in healing time between collagen and hydrocolloid (log rank 0.73, P ϭ .394).
Safety
Physicians unassociated with the trial adjudicated all adverse events. There were no adverse events rated as possibly, probably, or definitely related to study treatment.
Cost Analysis
The average cost was determined per patient to treat one pressure ulcer for 8 weeks with collagen or hydrocolloid Figure 2 . Cumulative probability of complete healing for patients with pressure ulcers treated with collagen (solid line) or hydrocolloid (dashed line). Treatment differences were not statistically significant. Note: Odds ratios (ORs) were calculated with the univariate logistic regression model. Ulcer duration before baseline assessment was obtained from nursing home nurse documentation. Area calculation employed the ellipse equation ϭ 1 ⁄ 4 ϫ (pi) ϫ (long axis length) ϫ (short axis length). CI ϭ confidence interval.
using the authors' standardized treatment protocols. The perspective was the nursing home provider. In the analysis, labor costs and times came from a survey of 11 nursing home sites. Acquisition costs were prices from a midwestern wholesaler. The cost model was acquisition cost ϩ (labor cost per hour ϫ hours per dressing change ϫ dressing changes per week ϫ 8 weeks) ϩ (ancillary supplies cost per dressing change ϫ dressing changes per week ϫ 8 weeks).
In the model, the average labor cost per hour was $15. 
DISCUSSION
This study was designed as a superiority trial to compare topical collagen with topical hydrocolloid in the treatment of pressure ulcers. After enrolling 65 patients with Stage II and III ulcers, a significant difference in healing rates between collagen and hydrocolloid could not be detected.
The results of all ulcer healing measurements were consistent with the primary endpoint. Ulcer depth at baseline was the only significant independent predictor of complete ulcer healing within 8 weeks. There was a nonsignificant trend favoring collagen for healing ulcers deeper than 2 mm at baseline. Collagen was more expensive than hydrocolloid and required more nursing interventions per week. In summary, there were no major benefits from collagen in patients otherwise eligible for hydrocolloid treatment. This study was not designed or powered to detect equivalence. The results would not support a claim of equivalence between collagen and hydrocolloid. However, the absolute risk difference between collagen and hydrocolloid was small, and the 95% CI included zero. When expressed as number needed to treat (NNT), the NNT (benefit) is 70 (95% CI NNT (harm) 4 to infinity to NNT (benefit) 4). 42 The clinical interpretation of the NNT is that 70 patients must be treated with collagen for up to 8 weeks before one additional healing event will occur in patients who would otherwise receive hydrocolloid treatment. The 95% CI includes the possible requirement for an infinite number of patients in a trial to demonstrate one additional healing event. The wide 95% CI around the NNT suggests that as few as four patients would need to be treated before one more or one less ulcer would heal. The width of the CI reflects the small sample size and the underlying variability in healing outcome in the pressure ulcer population.
These data do not exclude the possibility of clinically relevant differences in a subset of this patient population. For example, patients with Stage III ulcers may derive less benefit from hydrocolloid. 10, 43, 44 This study did not have the statistical power to confirm worse outcomes with hydrocolloid in deep ulcers. However, the trend in the data would support the hypothesis for a future trial in patients with Stage III pressure ulcers.
Previous randomized controlled trials of hydrocolloid 6, 13, 45, 46 are not fully comparable with this trial. Comparability is low because of a wide range of ulcer healing rates. 6, 13 Furthermore, previous trials did not employ blinded assessors or analyzed more than one ulcer per patient, 6 or did not include all randomized patients in the analysis. 6, 45 Previous controlled trials of collagen in wound treatment are not necessarily comparable with this trial. Other studies lacked random treatment allocation and blinded outcome assessment. In addition, previous trials enrolled smaller sample sizes 18 or employed potentially biased designs with two adjacent treatments on the same ulcer. 20 This study was not designed to analyze all potential risk factors associated with pressure ulcer healing. However, the data support previous studies and guidelines that emphasize assessment of ulcer depth, area, stage, or duration. 1, 22, 27, 30, 41, [47] [48] [49] In this study, initial ulcer depth was the most important independent predictor of healing outcome. Covariate analysis confirmed some studies 40 and contrasted with others. 1, 48 Differences in technique for assessing ulcer depth may explain the heterogeneity among studies. The covariates identified by this study and others have important implications for pressure ulcer research. Clinical trial protocols should prospectively use stratification or covariate analysis to address potential biases from initial ulcer depth, stage, area, and duration. The data in this report confirmed that the factors associated with pressure ulcer development 26 are not necessarily the same factors that predict healing. 41 For example, the Braden Scale is a validated predictor of ulcer development and includes subscales for malnutrition, immobility, and incontinence. 7 Epidemiological studies associate healing with nutrition, 47 mobility, 41 and continence, 41 among other variables. The authors of this study hypothesized that the Braden Scale might function as a predictor of pressure ulcer healing, but the exploratory analysis revealed no significant association.
This trial had several limitations. To maintain the blind study criteria, ulcers were irrigated before inspection by observers. Irrigation prevented reliable ascertainment of exudate and slough, which are important variables in ulcer assessment. 1, 22, 30, 48 The study transpired in nursing homes. Therefore, the results may not apply to inpatient management with different treatment protocols and higher acuity. The results may not extrapolate to the home care environment, where family members may deliver care. There was heterogeneity in healing outcome among nursing homes, and the sample size was inadequate to adjust for potential effects of the nursing home variable. Most likely the center effect was small. Only one nursing home was an outlier in achieving complete healing in 11 of 13 patients, whereas there was no difference in healing rates between the remaining nursing homes. This study enrolled patients with Stage II and III pressure ulcers. Generalization of these results to patients with Stage I and IV ulcers is not appropriate. Finally, the cost analysis may not be applicable outside of Illinois.
In summary, differences in healing outcomes or rates were not detected between collagen and hydrocolloid. Collagen treatment was more expensive than hydrocolloid treatment. Future trials should address the potential benefit of collagen versus hydrocolloid in deep Stage III pressure ulcers. When designing future trials, investigators should consider stratification for initial ulcer depth or stage. Prespecified post hoc analyses should adjust for baseline ulcer area and duration.
